METHODS: We utilized patient data prospectively collected from a "Phase 2 trial of neoadjuvant axitinib in patients with locally advanced non-metastatic clear cell renal carcinoma" (NCT01263769). Patients received axitinib for up to 12 weeks prior to surgical extirpation. Mass spectrometry-based proteome analysis was performed on urine samples collected both prior to treatment and at week 19 (6-7 weeks post-operatively). Linear regression models were used to model the relationship between the percent decrease in tumor diameter and urinary protein values. Cox proportional hazards models were used to identify associations with pre-operative protein levels and response to axitinib and survival outcomes.
INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most common type of kidney malignancy. At present, we do not have a simple, minimally invasive and economic diagnostic method for RCC. Circulating cell free DNA (cfDNA) can be found in biological fluids and it has been proposed as biomarker for several cancers other than RCC. Our aim was to explore the diagnostic and prognostic value of the assessment of cfDNA in urine for RCC.
METHODS: We prospectively recruited 23 patients with RCC, of whom 12 had clear cell RCC (ccRCC), 9 had papillary RCC (pRCC) and 2 had chromophobe RCC (chRCC). We collected three samples from each individual: a first morning urine sample at recruitment (before surgery), another 3 months after surgery and another 1 year after surgery. In addition, we recruited 23 healthy controls with normal renal and bladder ultrasound, matched for age and sex with patients, from whom we obtained a first morning urine sample. We evaluated and optimized the performance of 5 DNA isolation kits for urine. Next, we isolated cfDNA from all urine samples and quantified by real-time quantitative PCR the expression level of cfDNA of six genes previously studied in other cancer types: AR, ERBB2, c-MYC, BCAS1, ACTB and STOX1. A standard curve was prepared with DNA isolated from the renal cell line HEK 293 and was used as reference for quantification. Statistical analysis was performed using R (v3.2.3).
RESULTS: The QIAampÒ Viral RNA Mini Kit (Qiagen), with several modifications, provided the best yield and purity in the cfDNA isolation from urine samples. We observed a significant increase in the expression level of c-MYC in patients with ccRCC compared to controls (P[0.024). The presence of DNA fragments of c-MYC in urine is associated with an increased risk of ccRCC (OR[ 2.82; ). Moreover, the expression level of c-MYC increased with severity in ccRCC patients: in stage 2 compared to stage 1 (OR[ 3.41; P[0.012) and in stage 3 compared to stage 1 (OR [ 2.59; 0.99-6.8; P[0.053) . In chRCC we observed a decrease in the expression level of STOX1 in the last sample (1 year after surgery), compared to the sample prior to surgery (P[0.012). This decrease in DNA fragments of STOX1 in urine is associated with a decrease in the risk of chRCC (OR[ 0.02; , what may indicate the remission of the tumour after surgery.
CONCLUSIONS: The expression level of c-MYC may be a novel and non-invasive diagnostic biomarker for ccRCC, the most frequent subtype of renal cancer. Additionally, the expression level of STOX1 may be a prognostic marker for chRCC. These promising results need to be confirmed in a larger population, for which we are currently recruiting more patients and controls in order to replicate and validate them. Julia Oto, M a Jos e Solmoirago, Jos e Vicente S anchez-Gonz alez*, Javier P erez-Ardavin, Emma Plana, David Herv as, Alvaro Fern andez-Pardo, Marina Yelo, C esar D. Vera-Donoso, Manuel Martínez-Sarmiento, Francisco España, Silvia Navarro, Pilar Medina, Valencia, Spain INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most common type of urinary malignancy. Clear cell RCC (ccRCC) is the predominant RCC subtype, accounting for 70-80% of RCC. microRNAs (miRs) are small non-coding RNAs that regulate protein expression. miRs have been proved to regulate cancer progression and represent potential diagnostic and prognostic biomarkers. Our aim was to find a profile of miRs in urine capable of distinguishing between ccRCC patients and controls.
METHODS: Two clinical groups were recruited: 54 RCC patients from whom three urine samples were obtained (t0[ before surgery, t1[3 months after surgery, t2[one year after surgery) and 58 healthy volunteers (controls) with an ultrasound scan to rule out urological tumours from whom one urine sample was obtained. The expression level of 179 miRs was studied in urine of 16 selected ccRCC patients (at t0 and t1) and 16 controls, age and gender matched, using the Serum/plasma Focus microRNA PCR Panel V4 (Exiqon). An endogenous reference miR was selected as that with the highest stability using RefFinder software. Normalization of miR expression was conducted with the DDCt method, and subsequently results were also normalized with the level of creatinine. Statistical analysis was performed using R (v3.2.3).
RESULTS: The most stable miR was miR-20a-5p and therefore we used it as endogenous reference. We adjusted an Elastic Net logistic regression model for the diagnosis of ccRCC using the miR expression levels in urine of patients at t0 and controls. This model included 3 miRs: miR-200a-3p, miR-34a-5p and miR-365a-3p. Moreover, with the Wilcoxon test we identified 5 dysregulated miRs comparing the miR expression level of patients at t0 and controls: miR-200a-3p, let-7d-5p, miR-205-5p, miR-34a-5p and miR-365a-3p. Furthermore, we identified 5 dysregulated miRs comparing patients at t0 and t1: let-7d-5p, miR-152-3p, miR-30c-5p, miR-362-3p and miR30e-3p. These last 5 miRs could be involved in the prognosis of ccRCC.
CONCLUSIONS: We have obtained a urine profile of 3 miRs with potential diagnostic value for ccRCC. We also identified 5 dysre5 dysregulated miRs comparing patients and controls discovering an easy and non-risk procedure to achieve a closer personalized follow-up in high-risk patients. Our findings could shed light on the molecular mechanism of ccRCC. Validation of our statistical models in a larger cohort of patients is required. The identification of noninvasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens.
METHODS: This study includes two independent cohorts of ccRCC patients who underwent surgery between March 2015 and May 2018. Urine specimens were collected at the time of surgery from all the patients, and for 71.7% of the patients, urine was collected also during follow-up. Fifty-four patients were male (69.2%) and 24 patients were female (30.7%) with a median age of 65.4 years old (range 36-84). All the cases presented a clear cell histotype of RCC at the histological examination. Urine samples were also collected from two groups of healthy donors of 34 and 36 individuals with characteristics comparable to the ccRCC patients included in the study.
RESULTS: We evidenced that miR-21-5p, miR-210-3p and miR-221-3p resulted up-regulated in these ccRCC vs matched adjacent normal fresh frozen tissues, while miR-185-5p and miR-145-5p did not show significant modulation. Our data evidenced that miR-210-3p resulted the most significantly up-regulated miRNA (p-value[0.0149) . To investigate whether the miRNAs deregulated in ccRCC tissues may serve as useful clinical biomarkers, we selected miR-21-5p, miR-210-3p and miR-221-3p to evaluate their expression in 78 urine specimens. Urine were collected at time of surgery and during follow-up (with 15 months as median of time from surgery) from two independent cohorts of ccRCC patients; urine specimens from healthy donors were analyzed as well. Of note, miR-210-3p resulted significantly up-regulated in urine specimens collected from ccRCC patients at the time of surgery, compared to healthy donors' samples, contrarily to miR-21-5p and miR-221-3p, which didn't show increased levels in urine despite their trend of up-regulation observed in tumour tissues.
Importantly, miR-210-3p levels resulted significantly reduced during follow-up in 56 ccRCC patients of the same cohort, for which follow-up urine samples were available. MiR-21-5p and miR-221-3p resulted unchanged also in the follow-up samples.
CONCLUSIONS: This study not only supports the identification of miR-210-3p as non-invasive biomarker for ccRCC management but also highlights that only specific onco-miRNAs are accumulated in urine specimens of ccRCC patients. Of note, the urine level of miR-210-3p resulted significantly reduced during follow-up samples highlighting this onco-miRNA as potential biomarker useful not only for diagnosis but also to assess complete resection or response to treatment of ccRCC patients.
Source of Funding: None

MP21-14 FLUVASTATIN POTENTIATES ANTICANCER ACTIVITY OF VORINOSTAT IN RENAL CANCER CELLS BY ACTIVATING AMP-ACTIVATED PROTEIN KINASE
Kazuki Okubo*, Makoto Isono, Takako Asano, Akinori Sato, Tokorozawa, Japan INTRODUCTION AND OBJECTIVES: The histone deacetylase (HDAC) inhibitor vorinostat acts against malignancies by inducing histone acetylation but attenuates its anticancer activity by activating the mammalian target of rapamycin (mTOR) pathway. The HMG-CoA reductase inhibitor fluvastatin has been shown to activate AMPactivated protein kinase (AMPK) and thereby suppress the mTOR pathway. We thought that fluvastatin would potentiate vorinostat's anticancer activity in renal cancer cells by suppressing vorinostatinduced mTOR activation.
METHODS: After renal cancer cells (Caki-2, ACHN, A498, Renca) were treated with vorinostat (2.5-5 µM) and fluvastatin (5-10 µM), their viability and clonogenicity were assessed by MTS assay and colony formation assay. In vivo efficacy was evaluated using murine subcutaneous tumor models. Annexin V assay was used to detect apoptosis. Induction of endoplasmic reticulum (ER) stress, histone acetylation, and the expression of AMPK, S6 ribosomal protein and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) were evaluated by western blotting. Protein aggregation was evaluated using fluorescence microscopy.
RESULTS: The combination of vorinostat and fluvastatin caused drastic apoptosis (up to 10-fold increase in annexin V-positive cells) and inhibited renal cancer growth synergistically (combination indexes < 1). It also suppressed colony formation significantly (p < 0.05). In murine subcutaneous tumor models using Renca cells, a 14-day treatment with 25 mg/kg vorinostat and 10 mg/kg fluvastatin was well tolerated and inhibited tumor growth significantly (p [ 0.0079). Mechanistically, fluvastatin activated AMPK and inhibited vorinostatcaused phosphorylation of S6 ribosomal protein and 4EBP1, thus inhibiting the activation of the mTOR pathway by vorinostat. Furthermore, the combination was shown to cause excessive unfolded protein accumulation and aggregation, thereby inducing ER stress. This ER stress induction was due to the AMPK activation because the AMPK inhibitor compound C significantly inhibited the combination-induced ER stress. Interestingly, we also found that fluvastatin enhanced vorinostat-induced histone acetylation synergistically.
CONCLUSIONS: Fluvastatin potentiates vorinostat's anticancer activity by activating AMPK and thereby inhibiting vorinostatinduced mTOR activation. ER stress induced by the combination is also a consequence of AMPK activation.
Source of Funding: none
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FUSOGENIC LIPOSOMES AS A NOVEL NANOTHERAPY AGAINST METASTATIC CLEAR CELL RENAL CELL CARCINOMA Jan Rudzinski*, Natasha Govindasamy, Konstantin Stoletov, Adrian Fairey, John Lewis, Edmonton, Canada INTRODUCTION AND OBJECTIVES: We conducted a whole human genome short hairpin RNA (shRNA) screen on highly motile human squamous cell carcinoma (Hep3) cells and identified a panel of novel functional genes that are required for successful metastatic dissemination in vivo. One such novel target gene encodes for C14orf142 which is upregulated in metastatic clear cell RCC. Short interfering RNA (siRNA) are double stranded RNAs capable of binding to and inducing the degradation of complementary messenger RNAs in the cytoplasm leading to silencing of functional proteins. Fusogenic liposome platform is formulated with fusion associated small transmembrane proteins such as P14 which ensures highly efficient siRNA delivery directly into the cellular cytoplasm. Our objective is to
